Scientists have developed a new transcriptomic clock that predicts biological age and mortality using gene activity patterns conserved across species. Longevity experts also recommend tracking specific biomarkers like fasting glucose, ApoB, and hs-CRP with optimal ranges to monitor health proactively. Regular biomarker testing from mid-30s onwards is encouraged for early detection of age-related changes.
Oral semaglutide demonstrated significant improvements in multiple cardiometabolic risk factors in adults with type 2 diabetes at high cardiovascular risk. The SOUL trial analysis showed reductions in systolic blood pressure, cholesterol, triglycerides, HbA1c, and body weight compared to placebo. These benefits were observed as early as 13 weeks and contributed to a 14% reduction in major adverse cardiovascular events.
A 30-year study of nearly 200,000 adults found that diet quality matters more than macronutrient ratios for heart health, with both healthy low-carb and low-fat diets reducing coronary heart disease risk equally.
CSL Limited has licensed global development and commercialization rights for clazakizumab to Eli Lilly outside of ESKD-related cardiovascular risk. CSL receives $100 million upfront and retains rights to the ESKD indication.
Eli Lilly reported positive Phase 3 results for retatrutide showing up to 71.2 lbs average weight loss, while stockpiling $1.5 billion of oral drug orforglipron ahead of anticipated FDA approval in April 2026.
